British scientists behind key COVID trial launch study to test monkeypox treatment

The team from Oxford University behind the so-called RECOVERY trial – which honed in on four effective COVID treatments – on Tuesday unveiled a new trial, dubbed PLATINUM, to confirm whether SIGA Technologies’ tecovirimat is an effective treatment for monkeypox.Sign up to receive daily headline news from Ottawa Citizen, a division of Postmedia Network Inc.By clicking on the sign up button you consent to receive the above newsletter from Postmedia Network Inc.

Siga’s drug, branded Tpoxx, has been cleared to treat diseases caused by the family of orthopoxvirus that includes smallpox, monkeypox and cowpox by the European Union and United Kingdom, but due to limited trial data it is generally only used in severe cases in Britain.Since smallpox has been eradicated, and cases of monkeypox and cowpox typically occur sporadically, studies to assess the effectiveness of the drug in infected people have so far not been carried out.

To assess the drug’s effectiveness, the rate at which lesions heal, the time taken until patients test negative for the virus, and the proportion of patients who require hospitalization due to complications will be tracked.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

U.K. to use lower dose of monkeypox vaccine to stretch supplyBritain’s Health Security Agency said patients at clinics in Manchester and London would soon get just one fifth the regular monkeypox vaccine dose as part of ongoing research Science is only absolute only until it is no longer convenient
Source: globeandmail - 🏆 5. / 92 Read more »